In treating cancer, two drugs often prove to be better than one. By that reasoning, Biogen Idec Inc. initiated a Phase III trial of the anti-CD80 monoclonal antibody galiximab combined with the anti-CD20 monoclonal antibody Rituxan (rituximab).
Contributing WriterIn treating cancer, two drugs often prove to be better than one. By that reasoning, Biogen Idec Inc. initiated a Phase III trial of the anti-CD80 monoclonal antibody galiximab combined with the anti-CD20 monoclonal antibody Rituxan (rituximab).
